phase readout
saveNCT06616584: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
community read0 votes
Sponsor: SWOG Cancer Research Network. Phase: PHASE2. Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
view source ↗Data sources
last refreshed 6h ago
Found something off?
same company · ±60 days · 6
- earningsREGENERON PHARMACEUTICALS, INC. earningsJan 28, 2027
- earningsREGENERON PHARMACEUTICALS, INC. earningsOct 30, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsOct 28, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsJul 30, 2026
- phase 2 completioncemiplimab: Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026
- earningsREGENERON PHARMACEUTICALS, INC. earningsApr 29, 2026
related news · 8
- biospaceRegeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
- biospaceRegeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial
- biospace10 companies hiring in New Jersey
- biospaceBioSpace 2027 Best Places to Work shines light on most admired employers
- biospaceThe top 12 companies hiring in biopharma now
- biospaceRegeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
- biospace8 companies hiring in New York
- biospaceGenmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
comments(0)
5-min edit window · permanent after that